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Abstract
Background: Patient-reported measures are increasingly recognized as important predictors of clinical outcomes in
peritoneal dialysis (PD). We sought to understand associations between patient-reported perceptions of the advantages
and disadvantages of PD and clinical outcomes.
Methods: In this cohort study, 2760 PD patients in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS)
completed a questionnaire on their PD experience, between 2014 and 2017. In this questionnaire, PDOPPS patients rated
17 aspects of their PD experience on a 5-category ordinal scale, with responses scored from − 2 (major disadvantage) to +
2 (major advantage). An advantage/disadvantage score (ADS) was computed for each patient by averaging their response
scores. The ADS, along with each of these 17 aspects, were used as exposures. Outcomes included mortality, transition to
hemodialysis (HD), patient-reported quality of life (QOL), and depression. Cox regression was used to estimate associations
between ADS and mortality, transition to HD, and a composite of the two. Logistic regression with generalized estimating
equations was used to estimate cross-sectional associations of ADS with QOL and depression.
Results: While 7% of PD patients had an ADS < 0 (negative perception of PD), 59% had an ADS between 0 and < 1
(positive perception), and 34% had an ADS ≥1 (very positive perception). Minimal association was observed between
mortality and the ADS. Compared with a very positive perception, patients with a negative perception had a higher
transition rate to HD (hazard ratio [HR] = 1.67; 95% confidence interval [CI]: 1.21, 2.30). Among individual items, “space
taken up by PD supplies” was commonly rated as a disadvantage and had the strongest association with transition to
HD (HR = 1.28; 95% CI 1.07, 1.53). Lower ADS was strongly associated with worse QOL rating and greater depressive
symptoms.
Conclusions: Although patients reported a generally favorable perception of PD, patient-reported disadvantages were
associated with transition to HD, lower QOL, and depression. Strategies addressing these disadvantages, in particular
reducing solution storage space, may improve patient outcomes and the experience of PD.
Keywords: Depression, Patient-reported measures, Patient selection, Peritoneal dialysis, Quality of life, Surveys and
questionnaires, Technique survival
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Background
In the United States (US), changes in dialysis reimburse-
ment policies have led to unprecedented growth in the
use of peritoneal dialysis (PD) since 2011 [1]. Compared
with facility hemodialysis (HD), PD is more cost-effective
[2, 3], is less technically demanding [4], minimizes the
exposure of patients to hospital-acquired infections [5], is
more feasible in rural and remote settings [6], and is asso-
ciated with better preservation of residual kidney function
[7, 8] – a factor associated with survival advantage among
patients receiving dialysis [9–12]. Commonly perceived
patient advantages of PD include enhanced opportunities
for rehabilitation and return to employment and improved
satisfaction and quality of life (QOL) [13]. Studies have
suggested that reasons patients select PD include less
interference with lifestyle, preference to be independent,
wanting to dialyze at night, and less requirement for travel
for dialysis treatments [13, 14]. However, patients also
view disadvantages to PD therapy, including “catheter
care,” “high frequency of dialysis in a day,” and “troubling
other people” [15]. Negative aspects of PD have been
cited as “problem with supplies,” “frequency/length of
treatment,” “bloating/pain,” “interference with sleep,”
and “change in daily routine” [16].
To help patients make an informed decision about
whether to pursue PD, nephrologists and other health
educators typically explain presumptive advantages and
disadvantages of this dialysis modality. However, there is
little insight into how patients performing PD typically
rate these potential advantages and disadvantages and to
what extent they impact overall satisfaction with PD
therapy and clinical outcomes. Therefore, a better un-
derstanding of what patients like and dislike about their
PD therapy may help inform those faced with a dialysis
modality decision and help prioritize strategies to im-
prove the PD patient experience, thereby potentially in-
creasing PD uptake and extending technique survival.
Based on responses to a standardized patient question-
naire (PQ), we analyzed data from the Peritoneal Dialysis
Outcomes and Practice Patterns Study (PDOPPS) to in-
vestigate: 1) patients’ perspectives of PD, including what
they consider to be advantages and disadvantages of
therapy; and 2) how patient outcomes differed based on
their views regarding PD therapy.
Methods
Data source and variables
The PDOPPS is an international prospective cohort
study in collaboration with the International Society of
Peritoneal Dialysis (ISPD) [17]. Patients ≥18 years of age
receiving chronic PD are selected randomly from na-
tional samples of PD facilities. This analysis includes
data from Australia/New Zealand (ANZ), Canada, Japan,
Thailand, the United Kingdom (UK), and the US from
2014 to 2017. Study details are provided at https://www.
dopps.org/OurStudies/PeritonealDialysisPDOPPS.aspx [17].
Data are collected using uniform and standardized data col-
lection tools, procedures, and processes implemented
across the Dialysis Outcomes and Practice Patterns Study
(DOPPS) Program. The PDOPPS was approved by a central
institutional review board (IRB) in the US, with IRB study
approval and patient consent obtained for each patient, as
required by national and local ethics committee regulations.
Data from US patients receiving care at large dialysis
organization (LDO) sites are imported from electronic
health records; data from non-LDO US and non-US pa-
tients were obtained from manual medical chart abstraction
and entered into a web-based data collection tool.
Patient-reported advantages and disadvantages of PD
were collected using the PDOPPS PQ, which was mailed
to each facility participating in the PDOPPS. All patients
who were consented into the PDOPPS were then asked
by the facility’s research coordinator or nurse to complete
the questionnaire at the time the patient visited the facility
for their routine visit. Completing this was voluntary, and
patients were able to participate in the study without
completing the questionnaire. Participants were included
in this analysis if they rated at least 10 of the 17 queried
aspects of their PD experience in the PQ. Of the 5274
patients who received a PQ, 2899 (55%) returned the
questionnaire, of whom 139 (3%) rated fewer than 10 of
the 17 queried aspects of their PD experience. As a result,
2760 (52%) PD patients were included in this analysis.
Forty-four patients filled out the PQ after follow-up
ended, and therefore, were excluded in the death/transi-
tion to HD analysis. Patients excluded from analysis were
slightly younger (mean age 58.6 vs. 60.9 years), had shorter
PD vintage (mean 1.34 vs. 1.99 years), and were more
likely to be on automated PD (APD; 74% vs. 62%)
(Additional file 1: Table S1).
Patients were asked in the PQ, “To what extent do you
feel the following aspects of your PD treatments are
advantages or disadvantages?” (see Fig. 1 for a list of all
17 items). Possible responses to each item were mea-
sured on a 5-category ordinal scale: major advantage
(coded as + 2), advantage (coded as + 1), neither an ad-
vantage nor a disadvantage (0), disadvantage (− 1), or
major disadvantage (− 2); or patients could answer “I do
not know.” For purposes of this analysis, we combined “I
do not know” and “neither an advantage nor a disad-
vantage” and labeled this as “neutral” (coded as 0). To
quantify each patient’s overall perspective regarding PD,
an advantage/disadvantage score (ADS) was computed
by averaging their response scores and categorizing into
four groups: -2 ≤ADS < 0 (overall disadvantageous);
0 ≤ADS < 0.5 (slightly advantageous); 0.5 ≤ADS < 1
(moderately advantageous); and 1 ≤ADS ≤2 (most
advantageous).
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In the same questionnaire, we also collected data on
other patient-reported outcomes (PROs), including: (i)
physical component summary (PCS) and mental compo-
nent summary (MCS) scores derived from the short form
(SF)-12, a subset of the Kidney Disease Quality of Life
(KDQOL)-36 questionnaire [18], where lower scores indi-
cated worse QOL; and (ii) depressive symptoms, assessed
by the 10-item version of the Center for Epidemiological
Studies Depression Screening Index (CES-D) [19]. From
these three variables, we defined three binary outcomes: (i)
PCS < 32; (ii) MCS < 40; and (iii) CES-D ≥ 10. The cutoff
points for PCS and MCS were chosen based on the lowest
quartile of the distribution of scores in the study popula-
tion, and CES-D ≥ 10 was chosen as a positive screen for
depressive symptoms based on prior literature [19].
Statistical analysis
We reported patient characteristics of the total study
population by ADS group. We estimated associations
between the ADS (exposure) and PROs using logistic
regression with generalized estimating equations, as-
suming an exchangeable working correlation to account
for clustering within facilities [20]. Associations were
measured as odds ratios (OR) with 95% confidence in-
tervals (CI), adjusted for the following potential con-
founders: country, an indicator (yes/no) of receipt of
dialysis within a US LDO, age, sex, body mass index
(BMI), time on PD, 13 summary comorbid conditions
(Table 1), serum albumin, 24-h urine volume, and pre-
vious HD treatment.
Cox regression was used to estimate the associations
between ADS and three time-to-event outcomes:
all-cause mortality; permanent transition to HD; and
a composite outcome of mortality or permanent tran-
sition to HD, whichever came first. Permanent trans-
fer to HD was defined as deemed permanent transfers
or temporary transfers from PD to HD that did not
return to PD within 12 weeks (84 days). Follow-up
time began upon completion of the PQ and was
left-truncated from the start of PDOPPS study enroll-
ment for analyses. Follow-up ended at the event of
interest (i.e., death and/or technique failure) or, if no
event occurred, 7 days after leaving the facility due to
transfer or change in renal replacement therapy mo-
dality, transplantation, end of the study phase, or the
most recent date of data availability (January 2018). If
a patient died within 7 days of permanent transfer to
HD, this patient would be counted as both a perman-
ent transfer to HD and a death. Models were strati-
fied by country and US LDO, accounted for facility
clustering using robust sandwich covariance estima-
tors; estimated hazard ratios (HR) and 95% CIs were
adjusted for the same covariates as listed above.
To better understand which components of the
ADS had the biggest impact on outcomes, for items
rated as a disadvantage by at least 10% of patients,
we dichotomized the responses (major disadvantage
and disadvantage vs. major advantage, advantage, and
neutral) and used the same modeling approach to
examine their individual associations with mortality,
transition to HD, PCS score, MCS score, and CES-D.
Fig. 1 Distribution of responses to 17 questions regarding “To what extent do you feel the following aspects of your peritoneal dialysis
treatments are an advantage or disadvantage?” *Indicates the aspects the authors had expected to be disadvantages of peritoneal treatment
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The P values were corrected for multiple hypothesis
testing using the Benjamini-Hochberg procedure [21].
For primary analyses, missing covariate values were im-
puted multiply using the Sequential Regression Multiple
Imputation Method by IVEware [22]. Results from 20
imputed data sets were combined for the final analysis
using Rubin’s formula [23]. The proportions of missing
data were < 10% for all imputed covariates, except for
BMI (13%) and 24-h urine volume (43%). All analyses
used SAS software, version 9.4 (SAS Institute, Inc).
Table 1 Patient characteristics by ADS
Overall ADS
Patient characteristic – -2≤ ADS < 0 0≤ ADS < 0.5 0.5≤ ADS < 1 1≤ ADS ≤2
N patients 2760 181 667 959 953
Age, years 60.9(14.2) 59.0(13.4) 59.7(14.3) 61.2(14.4) 61.8(14.1)
Sex, % male 59% 61% 64% 57% 56%
BMI, kg/m2 26.8(6.1) 25.7(5.5) 26.3(6.0) 27.1(6.2) 27.2(6.0)
PD vintage, years 1.99(2.24) 1.80(2.02) 2.04(2.59) 1.94(2.10) 2.04(2.15)
PD modality, % APD 62% 43% 56% 64% 67%
Day dwell, % 66% 71% 70% 67% 60%
Comorbid conditions (%)
Coronary artery disease 21% 17% 21% 22% 21%
Cancer (non-skin) 11% 8% 11% 10% 13%
Other cardiovascular disease 14% 10% 13% 15% 14%
Cerebrovascular disease 10% 11% 11% 10% 9%
Congestive heart failure 15% 18% 14% 15% 14%
Diabetes 44% 51% 45% 42% 43%
Gastrointestinal bleeding 2% 2% 2% 2% 2%
Hypertension 91% 93% 92% 89% 90%
Lung disease 5% 5% 5% 6% 5%
Neurologic disease 4% 8% 4% 4% 4%
Psychiatric disorder 12% 13% 12% 13% 12%
Peripheral vascular disease 13% 9% 15% 11% 13%
Gangrene/recurrent cellulitis 2% 3% 2% 1% 1%
Peritonitis in last 4 months, % 8% 10% 8% 9% 7%
Albumin, g/dL 3.45(0.56) 3.28(0.60) 3.42(0.57) 3.47(0.53) 3.47(0.56)
24-h urine volume, L 0.95(0.76) 0.74(0.59) 0.92(0.77) 0.96(0.76) 1.00(0.78)
Prescribed therapy volume, L/day 7.92(3.92) 7.72(3.24) 7.82(3.70) 7.94(4.09) 8.02(4.01)
Peritoneal Kt/V urea 1.39(0.53) 1.37(0.48) 1.42(0.52) 1.37(0.50) 1.40(0.56)
Treated with HD treatmentsa, % 42% 39% 44% 39% 45%
Require help setting up/performing PD treatments
Never 69% 56% 64% 70% 75%
Some of the time 17% 22% 21% 16% 14%
All of the time 14% 22% 15% 13% 11%
Living arrangement
Lives alone 14% 17% 14% 15% 14%
Lives with spouse, family, or friends 83% 77% 84% 83% 84%
Nursing home, institution, or assisted living unit 1% 3% 1% 0% 1%
Unknown 2% 2% 1% 2% 1%
Homeless 0% 1% 0% 0% 0%
aFacility-based or hospital-based HD treatments. Mean (standard deviation) or % shown
Abbreviations: ADS advantage/disadvantage score, APD automated peritoneal dialysis, BMI body mass index, HD hemodialysis, PD peritoneal dialysis
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Results
Patient-reported advantages and disadvantages of PD
Figure 1 summarizes how patients rated each of the 17
items related to their perceived advantages and disadvan-
tages of PD. The factor most commonly perceived as an
advantage (i.e., advantage or major advantage) was “re-
ceive treatment at home” (94% of respondents), followed
by “do not require accessing of blood” (84%). The most
commonly rated disadvantage (i.e., disadvantage or major
disadvantage) of PD treatment was “feeling a full or
bloated sensation with my PD fluid in my abdomen”
(39%), followed by “space taken up by PD supplies” (32%).
Figure 2 shows the distribution of the ADS by country.
Japan and Thailand had the highest proportion of pa-
tients with a negative rating (ADS < 0, 11% within both
countries), compared with 3–6% elsewhere. The majority
of patients had a positive rating; 22–43% with ADS ≥1;
and 32–42% with 0.5 ≤ADS < 1.
Patient characteristics by ADS
Table 1 shows patient demographic and clinical factors
by ADS category. The median ADS was 0.76 (interquartile
range [IQR]: 0.41, 1.12), and only 7% had an ADS < 0
(overall negative perception of PD). Patients with a lower
ADS were younger (mean age 59.0 years for ADS < 0 vs.
61.8 years for 1 ≤ADS ≤2), had higher prevalence of dia-
betes (51% of patients with ADS < 0 vs. 42–45% in other
ADS groups), lower albumin (3.28 g/dL for ADS < 0 ver-
sus 3.42–3.47 in other ADS groups), and lower residual
kidney function (24-h urine volume 0.74 L vs. 0.92–1.00
L). Patients with the lowest ADS scores needed more as-
sistance to help set up and perform PD treatments.
ADS and adverse clinical outcomes
The median length of follow-up was 15.2 months (IQR:
8.0–24.5 months). During follow-up, 339 (12%) patients
died, 553 (20%) permanently switched to HD, and 886
composite events (death or transition to HD) were re-
corded. Compared with an ADS ≥1, patients with an
overall negative perception of PD (ADS < 0) were most
likely to transition to HD (HR = 1.67; 95% CI: 1.21, 2.30)
(Fig. 3a). There was little association between ADS and
all-cause mortality.
ADS and additional PROs
Nearly 21% of patients with an ADS < 0 reported that
they regretted the decision to start dialysis, compared
with only about 5% of patients with an ADS ≥1. Patients
with an ADS < 0 were also more likely to have restless
sleep, as 28% had restless sleep most of the time (5–7
days), compared with 13% of patients with an ADS ≥1.
Particularly, patients with an ADS < 0 on APD were
more often bothered by restless sleep (34% had restless
sleep most of the time) compared with patients with an
ADS < 0 on continuous ambulatory PD (CAPD; 22%). A
slightly higher percentage of patients with an ADS < 0
had peritonitis in the prior 4 months when compared
with patients with an ADS ≥1 (10% vs. 7%). Lower ADS
was associated with lower PCS and MCS scores of the
KDQOL and higher CES-D scores. Compared with pa-
tients with ADS ≥1, the adjusted ORs (95% CI) for pa-
tients with ADS < 0 were 8.68 (5.64, 13.4) for CES-D
score ≥ 10, 5.74 (4.09, 8.04) for MCS < 40, and 4.18
(2.75, 6.34) for PCS < 32 (Fig. 3b).
Fig. 2 Distribution of ADS, by country. Patient responses are coded −2 (major disadvantage) to + 2 (major advantage). A higher score,
calculated from this Likert scale, reflects a more favorable perception of PD. “I do not know” was treated the same as “neither advantage
nor disadvantage”
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Association between top eight disadvantage items and
outcomes
There were eight individual items rated as a disadvantage
by more than 10% of patients. Each item was inconsist-
ently and only weakly associated with mortality, transition
to HD, or the composite outcome (Fig. 4a), and this is
consistent when p values were corrected using the
Benjamini-Hochberg procedure. The item most strongly
associated with transition to HD was “space taken up by
PD supplies” (HR = 1.28; 95% CI: 1.07, 1.53), followed by
“impact or burden on family” (HR = 1.20; 95% CI: 0.97,
1.49), and “maintain or apply for job” (HR = 1.19; 95% CI:
0.96, 1.48). Select patient charateristics associated with
perception of “space taken up by PD supplies” are shown
in Additional file 1: Table S2. The reporting of each of
the eight items as a disadvantage was positively associ-
ated with poor QOL scores and a high depression score
(Fig. 4b).
Discussion
In this large, international study evaluating patient per-
ceptions of PD, there were four principal findings. First,
Fig. 3 Associations (adjusted HRs and 95% CIs) between the ADS and: a all-cause mortality, transition to HD, and the composite outcome
(mortality or transition to HD); and (b) measures of poor QOL and depression symptoms. The ADS was computed for each patient, where patient
responses are coded − 2 (major disadvantage) to + 2 (major advantage). A higher ADS reflects a more favorable perception of PD. PCS and MCS
scores were derived from the SF-12, with lower scores indicating worse QOL, and depressive symptoms were assessed by the 10-item version of
the CES-D, where CES-D≥ 10 was a positive screen for depressive symptoms. All models adjusted for the following potential confounders: age,
sex, BMI, time on PD, 13 summary comorbid conditions (Table 1), serum albumin, 24-h urine volume, and previous HD treatment. Models for: a
were stratified by country and US LDO; and for (b) were additionally adjusted for country and US LDO
Fig. 4 Association between the reporting of an item as a disadvantage and: a subsequent hazard of death, HD transition, or both; and (b)
measures of poor QOL and depression for each of the eight items, in which more than 10% of patients scored that item as a disadvantage of PD.
The reference group consisted of patients who reported the item as an advantage or neutral. PCS and MCS scores were derived from the SF-12,
with lower scores indicating worse QOL, and depressive symptoms were assessed by the 10-item version of the CES-D, where CES-D≥ 10 was a
positive screen for depressive symptoms. All models adjusted for the following potential confounders: age, sex, BMI, time on PD, 13 summary
comorbid conditions (Table 1), serum albumin, 24-h urine volume, and previous HD treatment. Models for: a were stratified by country and US
LDO; and for (b) were additionally adjusted for country and US LDO. Abbreviations: ADS advantage/disadvantage score, BMI body mass index,
CES-D Center for Epidemiological Studies Depression Screening Index, CI confidence interval, HD hemodialysis, HR hazard ratio, LDO large dialysis
organization, MCS mental component summary, PCS physical component summary, PD peritoneal dialysis, QOL quality of life, SF short form, US
United States
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PDOPPS patients in all countries reported many more
advantages of PD than disadvantages, with a median
ADS of 0.76. Second, we found that patients with an
overall negative perception of PD were more likely than
patients with a positive perception to transfer to HD.
Third, among individual components of the ADS, we
found that the two most frequently reported disadvan-
tages were “feeling full with PD fluid in abdomen” and
“space taken up by PD supplies”; however, only the latter
perceived disadvantage was also associated with transfer
to HD. Fourth, patients with more negative perceptions
of PD were more likely to have worse QOL scores and
more depressive symptoms.
In a study validating the Customer Satisfaction Ques-
tionnaire developed by Fresenius Medical Care, the com-
posite satisfaction score was found to be a good overall
measure of patient satisfaction in PD care, but associa-
tions of subscale domains with the total score suggested
that efforts focused on improving specific aspects might
be more effective in increasing patient satisfaction [24].
Hence, we evaluated individual components of the ADS
and found that “impact or burden on family,” “maintain
or apply for job,” and “space taken up by PD supplies”
were associated with transfer to HD. While the oppor-
tunity for employment continues to be a perceived ad-
vantage of PD (compared with HD), patients may view
“maintain or apply for a job” as a disadvantage if they
are comparing this with employment prior to starting
dialysis (vs. what employment while on HD was or
would be like), or perhaps if the ability to “maintain or
apply for a job” did not live up to their expectations of
the freedom they were counseled to expect with PD.
While the loss of employment has been shown to be
similar after initiation of HD or PD [25], studies have
also shown a significantly higher loss of employment
with HD, compared with PD [26]. However, any type of
dialysis is likely to be somewhat restrictive, and the
benefit of maintaining or applying for a job while on PD
may be more of a theoretical advantage. “Space taken up
by PD supplies” was the second most commonly rated
disadvantage, underscoring the impact of the space re-
quired to store PD supplies. Lack of space at home is a
frequently-reported barrier among prevalent HD pa-
tients when even simply considering home dialysis [27].
While we did not suspect an association of “space taken
up by PD supplies” with mortality, we did hypothesize
the association with transfer to HD, given that the out-
come of transfer to HD is generally more likely to be
patient-driven, compared with the outcome of mortality.
It is reasonable to assume that patients are more likely
to view this storage space aspect negatively if their living
space is small, especially if they have to share their living
space. The average residential floor space per capita in
the UK is 356 square feet (33.1 m2) versus 832 square
feet (77.3 m2) in the US [28], and likely accounts, in part,
for the higher percentage of patients in the UK who
viewed “space taken up by PD supplies” as a disadvan-
tage than in the US (Additional file 2: Figure S1). Pa-
tients with larger prescribed fluid volumes were more
likely to view “space taken up by PD supplies” as a disad-
vantage (Additional file 1: Table S2), and strategies that
minimize total PD fluid needs may be advantageous.
However, it is essential that patient care not be compro-
mised by reducing treatment volumes or omitting
day-time dwells in an attempt to decrease total PD fluid
needs, as this may lead to inadequate dialysis with im-
paired sodium (and thereby fluid) removal and inad-
equate middle molecule clearance. While lower
dialysate dwell volumes could potentially be advanta-
geous in the new patient, using incrementally larger
volumes as needed with the decline of residual kidney
function over time, another strategy could be more fre-
quent delivery of supplies, which would reduce the
number of boxes in the home at any one time, thereby
minimizing the space required for storage without re-
ducing the fluid prescription. Additionally, there is
likely to be an emotional component related to viewing
“space taken up by PD supplies” as a disadvantage,
since the large boxes that occupy space in the home
possibly serve as a reminder to the patient that they are
living with a chronic disease. Novel technologies may
soon enable patients to create dialysate fluid on-site,
thereby reducing storage requirements. Future studies
will be needed to evaluate whether and to what extent
reducing the burden of solution storage may minimize
negative perceptions of PD and, therefore, possibly pro-
long PD technique survival.
Patients with a less favorable perception of PD were
younger, had a lower BMI, and had lower 24-h urine vol-
umes (Table 1). Patients with lower BMIs may be more
sensitive to their dwell volumes, possibly feeling full
more easily, and, therefore, may view PD more nega-
tively. Additionally, those with lower 24-h urine volumes
may try to achieve greater peritoneal ultrafiltration with
greater fill volumes, thereby further contributing to a
feeling of fullness. We found that patients using APD
tended to view PD more positively than those using
CAPD, similar to previous findings [29]. Patients using
APD accomplish the majority of their therapy at night
while sleeping, allowing more flexibility with their time
during the day. Similarly, we found those with a “day
dwell” viewed PD more negatively, as the effect of grav-
ity while patients are upright likely causes more discom-
fort. The lowest ADS category had a higher percentage
of patients who required help setting up and performing
PD treatments; this supports previous reports, whereby
PD patients commonly listed “troubling other people” as
a main disadvantage of PD [15].
Sukul et al. BMC Nephrology          (2019) 20:116 Page 7 of 10
In the analysis of PROs, lower ADS scores – suggest-
ing a more negative perception of PD – were associated
with lower scores of physical and mental health and
increased symptoms of depression. It is possible that the
direction of this association may be such that the nega-
tive perception of PD led to inferior QOL and greater
depression. Equally plausible is that this association may
be the result of patients with impaired QOL and depres-
sion at baseline, which impacted their perception of PD.
Previous studies have demonstrated an independent as-
sociation between depression and increased mortality
risk in dialysis patients [30], as well as an independent
association between depression and peritonitis rates
[31], which is a common cause of transfer to HD [32].
This study should be viewed in the context of the
following limitations. First, given the observational study
design, we cannot rule out residual confounding due to
unmeasured risk factors or model misspecification. For
example, we did not collect information on the sizes and
locations of patients’ homes, which may have explained
some of our findings. Second, as previously mentioned,
since the analyses between ADS and the PROs of MCS,
PCS, and CES-D scores were cross-sectional, the possi-
bility of reverse causation limits the ability to assume a
causal relationship. Third, the cross-sectional analyses are
also susceptible to selection bias because the survey out-
comes could have influenced the selection of subjects,
which is especially true in this study, given that the survey
response rate was only slightly better than 50%. However,
as shown in Additional file 1: Table S1, there were no large
differences between survey respondents and
non-respondents. Fourth, the high proportion of PD pa-
tients reporting favorable views of PD might have been ex-
aggerated due to the possible tendency of patients to
answer those survey questions in ways they thought were
expected or desired by the investigators. Finally, while most
validated questionnaires currently assess QOL among PD
patients, one validated survey assigns priority to aspects of
the dialysis patient experience based on patient responses,
but only a single aspect relates to PD specifically: “immedi-
ate help in case of peritonitis” [33]. Although the survey
questions of our 17-item questionnaire were generated
based on expert consensus, many of the items overlap with
what long-term PD patients have identified as reasons for
choosing PD [34]. However, while little prior literature or
psychometrics informed the content of our survey, this will
serve as a stepping stone for future work in developing a
validated questionnaire, using more patient engagement, to
meaningfully assess the balance between patient-perceived
PD advantages and disadvantages.
Conclusions
This is the largest study to-date to include PROs on PD
patients, and we found associations between an overall
negative perception of PD therapy and a higher rate of
transferring to HD, worse QOL scores, and more de-
pressive symptoms. Moreover, patients who viewed
“space taken up by PD supplies” as a disadvantage had a
higher rate of transferring to HD. Our findings will assist
nephrologists and members of the end-stage kidney dis-
ease (ESKD) care team to better provide more informed
counseling with quantifiable advantages and disadvan-
tages to patients considering PD as their dialysis modal-
ity. Additionally, given the possible influence of reverse
causation in the cross-sectional findings of this paper,
not only could improving the perceived disadvantages of
therapy improve QOL and depression, but efforts di-
rected at enhancing support for patients’ physical and
mental well-being and improving depression symptoms
may help improve patients’ perceptions of PD therapy.
Future studies are needed to determine the extent to
which the expected advantages and disadvantages of PD
in pre-ESKD patients are similar to the perceptions of
those patients after starting PD, as this will allow for
more accurate and personalized counseling of ESKD pa-
tients considering PD. Finally, given that “space taken up
by PD supplies” is a commonly perceived disadvantage,
and that this perception is associated with an increased
likelihood of transferring to HD, modifying therapy with
new technologies, such as on-site PD fluid creation, may
positively affect the patient’s experience and is worth
further investigation.
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